Áp lực kép “rút thanh khoản lớn + liên tục bán ra” khiến ZKJ và KOGE lần lượt sụp đổ

Boehringer Ingelheim Venture Fund

company

About

Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.

  • 11 - 50

Details

Industries
Biotechnology,Finance,Venture Capital
Founded date
Jan 1, 2010
Number Of Employee
11 - 50
Operating Status
Active
Investor Type
CVC

Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy.

Investments

Number of Investments
Number of Lead Investments
7
2
Boehringer Ingelheim Venture Fund has made 7 investments. Their most recent investment was on Nov 29, 2022, when Rgenta Therapeutics raised $52M.
Date Company Name
Round Money Raised Industry Lead Investor
Series A $52M Biotechnology
Seed $20M Biotechnology Yes
Series B €10M Biotechnology
Series A €27M Biotechnology
Series A €2.50M Biotechnology Yes